ReviewLung cancer management2026

Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.

Mengmeng Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.